lucentis
novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologicals - Луцентис prikazan kod odraslih za liječenje неоваскулярной (vlažna) senilne makularne degeneracije (amd)liječenje vida zbog хориоидальной неоваскуляризации (ХНВ)poremećaje vida zbog dijabetes pomagala макулярного edema (ДМО)poremećaje vida zbog макулярного edema sekundarne okluzije ретинальных vena (branch ili središnji glr glr).
lucentis 10 mg/1 ml rastvor za injekciju
novartis ba d.o.o. - ranibizumab - rastvor za injekciju - 10 mg/1 ml - 1 ml rastvora za injekciju sadrži: 10 mg (2,3 mg/0,23 ml) ranibizumaba
lucentis 10 mg/1 ml rastvor za injekciju
novartis ba d.o.o. - ranibizumab - rastvor za injekciju - 10 mg/1 ml - 1 ml rastvora za injekciju sadrži: 10 mg (2,3 mg/0,23 ml) ranibizumaba
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
lucentis 10mg/ml rastvor za injekciju
"novartis pharma services ag" dio stranog druŠtva podgorica - ranibizumab - rastvor za injekciju - 10mg/ml
ikervis
santen oy - ciklosporin - bolesti rožnice - ophthalmologicals - liječenje teške keratitisa u odraslih bolesnika s suho oko bolesti, što je oplemenjen usprkos suza zamjene.
lapovis plus 50 mikrograma/ml + 5 mg/ml kapi za oko, otopina
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - latanoprost timololmaleat - kapi za oko, otopina - 0,05 mg/ml + 5 mg/ml - urbroj: jedan ml otopine sadrži 50 mikrograma latanoprosta i 5 mg timolola (u obliku timololmaleata)
unilat 50 mikrograma/ml kapi za oko, otopina
unimed pharma spol. s r.o., orieskova 11, bratislava, slovačka - latanoprost - kapi za oko, otopina - 50 mikrograma/ml - urbroj: 1 ml otopine sadrži 50 mikrograma latanoprosta